Literature DB >> 19941076

PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population.

Francesco M Carpi1, Silvia Vincenzetti, Daniela Micozzi, Alberto Vita, Valerio Napolioni.   

Abstract

Cytidine deaminase (CDA) is a pyrimidine salvage pathway enzyme that catalyzes the hydrolytic deamination of cytidine and deoxycytidine to their corresponding uracil nucleosides. CDA also catalyzes the inactivation of some chemotherapeutic nucleoside analogues such as cytosine arabinoside and gemcitabine. CDA 79A > C (K27Q, rs2072671) and 208G > A (A70T, rs60369023) were found to be associated either with clinical outcomes as well as with pharmacokinetics and toxicity of drugs administered to different subsets of patients. In this paper we reported two PCR-based methods for CDA 79A > C (K27Q) and 208G > A (A70T) genotyping and tested their feasibility using DNA extracted from whole blood as well as from buccal swabs. The aim of this study was also to assess the distribution of genotypic variants in a central Italy population. The allele frequencies were 56.3% (K*) and 43.7% (Q*) for K27Q and 100% (A*) and 0% (T*) for A70T. The genotype frequencies were 32.8% (K*/K*), 46.9% (K*/Q*) and 20.3% (Q*/Q*) for K27Q. The genotype frequencies did not deviate from Hardy-Weinberg equilibrium. The results were compared with those of other reported populations. They showed marked ethnic group differences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941076     DOI: 10.1007/s11033-009-9923-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  20 in total

1.  Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.

Authors:  A K Fukunaga; S Marsh; D J Murry; T D Hurley; H L McLeod
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.

Authors:  H C Kirch; J Schröder; H Hoppe; H Esche; S Seeber; J Schütte
Journal:  Exp Hematol       Date:  1998-05       Impact factor: 3.084

4.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.

Authors:  D H Ho; E Frei
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

5.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.

Authors:  Sara M Fitzgerald; Rakesh K Goyal; William R A Osborne; Jennifer D Roy; John W Wilson; R E Ferrell
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

6.  Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

Authors:  J K Schröder; C Kirch; S Seeber; J Schütte
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

7.  Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA.

Authors:  J Laliberté; R L Momparler
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

8.  Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.

Authors:  Deepika Bhatla; Robert B Gerbing; Todd A Alonzo; Heather Conner; Julie A Ross; Soheil Meshinchi; Xiaowen Zhai; Tiffany Zamzow; Parinda A Mehta; Hartmut Geiger; John Perentesis; Stella M Davies
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

9.  Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex.

Authors:  L Betts; S Xiang; S A Short; R Wolfenden; C W Carter
Journal:  J Mol Biol       Date:  1994-01-14       Impact factor: 5.469

10.  Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

Authors:  Helen K Chew; James H Doroshow; Paul Frankel; Kim A Margolin; George Somlo; Heinz-Josef Lenz; Michael Gordon; Wu Zhang; Dongyun Yang; Christy Russell; Darcy Spicer; Tim Synold; Robert Bayer; Alexander Hantel; Patrick J Stiff; Merry L Tetef; David R Gandara; Kathy S Albain
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

View more
  2 in total

1.  Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.

Authors:  Daniela Micozzi; Francesco Martino Carpi; Stefania Pucciarelli; Valeria Polzonetti; Paolo Polidori; Santiago Vilar; Brian Williams; Stefano Costanzi; Silvia Vincenzetti
Journal:  Int J Biol Macromol       Date:  2013-10-29       Impact factor: 6.953

2.  Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.

Authors:  Aurora Medina-Sanson; Arturo Ramírez-Pacheco; Silvia Selene Moreno-Guerrero; Elisa María Dorantes-Acosta; Metzeri Sánchez-Preza; Alfonso Reyes-López
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.